Funding Opportunity RFA-DK-17-022 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites cooperative agreement applications that will contribute to a higher resolution understanding of the physical and functional organization of the human islet tissue environment by describing the composition (cellular and molecular) and function of important components of the pancreatic islet and peri-islet tissue architecture, the cell-cell relationships and means of communications used by cell types and cell subtypes within the pancreatic tissue ecosystem, and/or the contribution of adjacent (including acinar, ductal, lymphatic) and neighboring (intestinal, mesenteric and adipose) tissues to islet cell function and dysfunction. Successful projects will integrate the Human Pancreas Analysis Consortium (HPAC), that will consist of the research teams funded in response to this FOA with the Human Pancreas Analysis Program (HPAP), a resource-generation program that was funded in 2016 in response to RFA-DK-15-027. HPAC will become the fifth consortium of the Human Islet Research Network (HIRN, https://hirnetwork.org/ ). HIRN's overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This FOA will only support studies with a primary focus on increasing our understanding of human tissue structure and function, and human disease biology (as opposed to rodent or other animal models). This FOA is not intended to support the conduct of a clinical trial.

Notice NOT-HD-18-003 from the NIH Guide for Grants and Contracts

Notice NOT-AI-18-020 from the NIH Guide for Grants and Contracts

Notice NOT-DA-18-005 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-18-660 from the NIH Guide for Grants and Contracts. The goal of this FOA is to develop new hypotheses and common experimental framework(s) between human - animal model studies to better understand the genetic, genomic, and epigenetic factors contributing to and underlying biological bases for the development of tolerance and the progression to alcohol dependence.

Funding Opportunity PAR-18-659 from the NIH Guide for Grants and Contracts. The intent of this FOA is two-fold: (1) develop new hypotheses about key factors and pathways in sensitivity and tolerance to alcohol, and (2) develop a common framework of mechanisms underlying the development of tolerance and the progression to alcohol dependence. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase.

Funding Opportunity RFA-CA-18-011 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. Projects proposed in response to this FOA must be applicable to one of the following areas: (1) cancer therapeutics; (2) cancer imaging technologies, interventional devices, and/or in vivo diagnostics; or (3) in vitro and ex vivo cancer diagnostics and prognostics. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required

Funding Opportunity RFA-AG-18-031 from the NIH Guide for Grants and Contracts. This RFA invites applications for planning awards to develop and finalize protocols for well-powered cognitive training intervention trials to remediate or prevent age-related cognitive decline as well as possibly prevent or delay the onset of mild cognitive impairment and dementia. Planning activities may include the collection of pilot data and the refinement of cognitive training protocols consistent with Stage I of the NIH Stage Model. Trial designs must justify the means used to assess cognition and to explore the underlying mechanisms of change. Such methods as structural and functional neuroimaging with biomarkers justified by an underlying model of change, CSF fluids, and blood biomarkers are appropriate candidate tools.

Funding Opportunity PAR-18-662 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated multi-site clinical trials (e.g. efficacy, effectiveness or pragmatic trials) to study the effects of mind and body interventions in NCCIH designated areas of high research priority. Clinical Coordinating Centers should develop and implement the proposed multi-site clinical trial. The objective of a Clinical Coordinating Center application is to present the scientific rationale and a comprehensive scientific and operational plan for the clinical trial. Clinical Coordinating Center applications are expected to describe plans for project management, participant recruitment and retention strategies, performance milestones , scientific conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this FOA will utilize a two-phase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism . In addition, an accompanying Data Coordinating Center application, submitted under PAR-18-116 (https ://grants.nih.gov/grants/guide/pa-files/PAR-18-116.html) proposing a data analysis and data management plan for the clinical project is required. Both a Clinical Coordinating Center application and a corresponding Data Coordinating Center (DCC) application need to be submitted simultaneously for consideration by NCCIH. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website : (https://nccih.nih.gov/about/plans (https://nccih.nih.gov/about/plans )). Applicants are encouraged to contact the appropriate the Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

Funding Opportunity PAR-18-663 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase Ill and beyond) application submitted under PAR-18-117 (https://grants.nih.gov/grants/guide/pa-files/PAR-18- 117.html}. The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this FOA applies must be relevant to the research mission of the NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (http://www.nccih.nih.gov (http://www.nccih.nih.gov)). Applicants are encouraged to contact the appropriate the Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

Funding Opportunity PAR-18-661 from the NIH Guide for Grants and Contracts. The purpose of the FOA is to support the large scale molecular platform analysis of brain tissue, human biofluid or human induced pluripotent stem cell resources for the identification of targets and pathways associated with Alzheimer's Disease Related Dementias (ADRDs) pathophysiology.

Funding Opportunity RFA-HD-19-004 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite SBIR applications to support and facilitate the development of new and/or improved contraceptive products for men and women.

Funding Opportunity PAR-18-664 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support rigorous clinical validation of a candidate biomarker using retrospective and/or prospective methods in a manner that is consistent with the purpose of the biomarker. This FOA assumes that: 1) a candidate biomarker has already been identified, 2) an analytical method has been developed and validated that is consistent with the purpose of the biomarker and 3) a working hypothesis regarding context of use is in place. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers of neurological disease for use in multi-site clinical trials and clinical practice.

Funding Opportunity RFA-DE-19-003 from the NIH Guide for Grants and Contracts. The NIDCR-funded FaceBase data repository and knowledgebase (www.facebase.org) was established to advance craniofacial research by creating comprehensive datasets on craniofacial development and dysmorphologies and disseminating them to the wider craniofacial research community. Since FaceBases inception, the data management and integration hub has been charged with the critical functions of collecting datasets and analytic tools developed by dataset-generating spoke projects, curating and integrating those resources, and disseminating them to the wider research community through the FaceBase website. This Request for Applications (RFA) solicits renewal applications for the role of the Data Management and Integration Hub. As in the past, the FaceBase 3 hub will continue to be responsible for integration and presentation of existing FaceBase datasets, development or adoption of new approaches for data search and visualization, and outreach to the wider craniofacial research community. In addition, the hub will assume an important new mission, that of working with investigators within the craniofacial research community to make their datasets compatible with FaceBases data models, curating and integrating these new datasets with those already held by FaceBase.

Notice NOT-DA-18-006 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-17-028 from the NIH Guide for Grants and Contracts. This FOA seeks applications for clinical trials testing interventions targeting diabetes distress in individuals with T1D and/or their caregivers, with the goal of understanding whether lowering diabetes distress will improve glycemic control and quality of life.

Funding Opportunity RFA-DK-17-027 from the NIH Guide for Grants and Contracts. This FOA will support research to test approaches in the healthcare setting to using Patient-Reported Outcomes (PROs) as tools to enhance patient-centered treatment and improve outcomes in individuals with type 1 diabetes.

Funding Opportunity RFA-DK-17-020 from the NIH Guide for Grants and Contracts. Type 1 diabetes (T1D) results in part from the autoimmune-mediated dysfunction or destruction of insulin-producing pancreatic beta cells. This funding opportunity is for projects that seek to discover ways to change the course of the disease by directly establishing tolerance. Immune responses could be engineered for tolerance induction through the manipulation of antigens, cells, or cellular microenvironments. Collaborations between T1D experts and investigators from other fields, including (but not limited to) cancer immunology and biomaterials engineering, are especially encouraged.

Funding Opportunity RFA-DK-17-032 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for studies of etiology and pathogenesis related to development of type 1 diabetes (T1D) and/or its complications. Studies must involve subjects enrolled and followed in clinical trials, long term follow-up, or observational studies. This opportunity is intended to fund collaborative projects that bring new expertise and innovative approaches to enhance the value of major ongoing clinical research projects.

Funding Opportunity RFA-DK-17-026 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement is intended to foster the development of a diverse and highly trained workforce of endocrinologists to assume leadership roles related to the Nations biomedical and behavioral research efforts in the area of type 1 diabetes (T1D). T1D is an autoimmune disease that occurs in both children and adults. Therefore, the NIDDK will award physician scientist career development program (K12) grants to eligible institutions to provide a program to prepare adult and/or pediatric endocrinologists, selected by the institution, for careers in basic or clinical research related to T1D. This Funding Opportunity Announcement (FOA) allows appointment of Scholars (K12) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary study to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development. Scholars may also propose fundamental research or human subjects research that is not a clinical trial.